Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer.

Asian J Androl · 2015 · PMC4814966 · PMID 25865849

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

5 In 2013, abiraterone acetate showed a trend toward overall survival in the predocetaxel setting leading to its FDA approval for chemotherapy-naïve patients. 6 The final analysis of COU-AA-302 was relased in 2015, which showed a statistically significant 4.4 month increase in the median overall survival with abiraterone acetate before chemoth

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.